2.79
1.76%
-0.05
After Hours:
2.75
-0.04
-1.43%
First Wave BioPharma Inc stock is currently priced at $2.79, with a 24-hour trading volume of 48,248.
It has seen a -1.76% decreased in the last 24 hours and a -31.62% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.78 pivot point. If it approaches the $2.92 resistance level, significant changes may occur.
Previous Close:
$2.84
Open:
$2.92
24h Volume:
48,248
Market Cap:
$5.65M
Revenue:
-
Net Income/Loss:
$-15.68M
P/E Ratio:
-6.4301
EPS:
-0.4339
Net Cash Flow:
$-14.53M
1W Performance:
+2.20%
1M Performance:
-31.62%
6M Performance:
+805.84%
1Y Performance:
+7.31%
First Wave BioPharma Inc Stock (FWBI) Company Profile
Name
First Wave BioPharma Inc
Sector
Industry
Phone
561 589 7020
Address
777 Yamato Road, Suite 502, Boca Raton
First Wave BioPharma Inc Stock (FWBI) Latest News
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
GlobeNewswire Inc.
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
GlobeNewswire Inc.
Here's Why First Wave BioPharma (FWBI) Is a Great 'Buy the Bottom' Stock Now
Zacks Investment Research
First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
GlobeNewswire Inc.
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
First Wave BioPharma Inc Stock (FWBI) Financials Data
First Wave BioPharma Inc (FWBI) Net Income 2024
FWBI net income (TTM) was -$15.68 million for the quarter ending September 30, 2023, a +28.13% increase year-over-year.
First Wave BioPharma Inc (FWBI) Cash Flow 2024
FWBI recorded a free cash flow (TTM) of -$14.53 million for the quarter ending September 30, 2023, a +35.75% increase year-over-year.
First Wave BioPharma Inc (FWBI) Earnings per Share 2024
FWBI earnings per share (TTM) was -$381.88 for the quarter ending September 30, 2023, a +86.05% growth year-over-year.
About First Wave BioPharma Inc
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases. The company is advancing a therapeutic development pipeline populated with various clinical stage programs built around its two proprietary technologies, known as niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its niclosamide portfolio is led by three clinical programs: FW-COV for COVID-19 gastrointestinal infections; FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis; and FW-ICI-AC for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients. Two additional formulations of niclosamide, FW-UC (ulcerative colitis) and FW-CD (Crohn's disease) are focused to enter into pipeline development. The company is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Cap:
|
Volume (24h):